Business Context and Reporting Period
Company: ProMIS Neurosciences Inc. (PMN)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2026
Business Overview: ProMIS is a clinical-stage biopharmaceutical company developing antibody therapies and vaccines for neurodegenerative diseases, including Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company utilizes a proprietary technology platform to target toxic, misfolded proteins. Key product candidates include PMN310 (AD), PMN267 (ALS), and PMN442 (Synucleinopathies).
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(8,244,372) | $(7,347,903) |
| Net Loss Per Share (Basic & Diluted) | $(1.26) | $(5.27) |
| Operating Expenses | $8,644,895 | $7,460,095 |
| Cash and Short-Term Investments (End of Period) | $63,848,098 | $8,398,054 |
| Net Cash Used in Operating Activities | $(12,383,520) | $(4,926,866) |
| Net Cash Provided by Financing Activities | $70,081,309 | $0 |
| Accumulated Deficit | $(138,650,592) | $(98,034,976) |
Note: Cash and Short-Term Investments calculated as Cash ($63,814,345) + Short-term investments ($33,753).
Material Changes vs. Prior Period
- Capital Raise: In January 2026, the Company completed a private placement (PIPE) raising net proceeds of approximately $70.1 million. This resulted in a significant increase in cash balances from $6.1 million at year-end 2025 to $63.8 million at March 31, 2026.
- Share Count: Common shares outstanding increased from 2,152,397 (Dec 31, 2025) to 8,967,693 (March 31, 2026) due to the PIPE issuance.
- Operating Expenses: Total operating expenses increased by $1.18 million (16%) year-over-year. Research and Development (R&D) expenses rose by $1.51 million (28%), primarily driven by increased activity in the PMN310 Phase 1b clinical trial. General and Administrative (G&A) expenses decreased by $0.32 million (16%), largely due to the absence of severance costs recognized in Q1 2025.
- Liquidity: The company moved from a negative shareholders' equity position of $(1.26) million at year-end 2025 to positive equity of $60.7 million following the capital raise.
Guidance, Outlook, and Risks
- Clinical Progress: The Phase 1b "PRECISE-AD" trial for PMN310 (Alzheimer's) completed enrollment of 144 subjects in December 2025. Six-month assessments are expected in Q2 2026, with blinded interim analysis anticipated in early Q3 2026. Top-line data is expected in early 2027.
- Liquidity Outlook: Management expects existing cash and short-term investments to fund operations through 2027. However, the company remains dependent on additional financing for future clinical activities and commercialization.
- Risk Factors:
- Capital Requirements: The company has an accumulated deficit of $138.7 million and expects to continue incurring losses. Failure to secure additional funding could force delays or termination of development programs.
- Development Risk: No product candidates have received regulatory approval. Clinical trials may fail to demonstrate safety or efficacy.
- Market Risk: The company is subject to risks associated with the biotechnology industry, including competition, patent challenges, and regulatory changes.
Investor Verification Checklist
- Cash Runway: Verify the specific assumptions used to project cash sufficiency through 2027, particularly regarding the timing of the PMN310 interim analysis and potential additional funding needs.
- PMN310 Trial Status: Monitor the upcoming Q2 2026 six-month assessment data and Q3 2026 interim analysis for safety (specifically ARIA risk) and biomarker efficacy.
- Dilution Impact: Review the terms of the January 2026 PIPE, including the exercise prices of the 6.9 million warrants issued ($14.40) and the potential for further dilution in future financings.
- Expense Trajectory: Assess whether the increase in R&D spend ($6.3M for PMN310 in Q1) is sustainable given the current cash balance and if G&A reductions are temporary or structural.